Key details on ImmunoGen (Ticker: IMGN)
- CUSIP: 45253H101
- Is IMGN overvalued or undervalued? Run a discounted cash flow (DCF) valuation analysis on IMGN
Who owns ImmunoGen?
Is IMGN a good stock to own? Find out who bought ImmunoGen, who sold ImmunoGen (IMGN) stock, and who holds a large position in ImmunoGen.
|Fund Name||Number of Shares||Share Valuation||As Of|
|ClearBridge Advisors||14.45M||$129.34M||March 31, 2015|
|PRIMECAP Management Company||12.87M||$123.53M||Sept. 30, 2015|
|Vanguard||12.22M||$117.40M||Sept. 30, 2015|
|FMR||7.26M||$69.67M||Sept. 30, 2015|
|First Trust Advisors||5.81M||$61.55M||Sept. 30, 2014|
|OrbiMed Advisors||3.59M||$34.50M||Sept. 30, 2015|
|Baker Bros. Advisors||3.55M||$34.06M||Sept. 30, 2015|
|BlackRock Fund Advisors||3.28M||$31.50M||Sept. 30, 2015|
|STATE STREET CORPORATION||3.23M||$30.97M||Sept. 30, 2015|
|Wellington Management Company||3.13M||$46.68M||March 31, 2014|
|BB Biotech AG||2.84M||$25.43M||March 31, 2015|
|BlackRock Institutional Trust Company, N.A.||2.29M||$32.95M||June 30, 2015|
|Sectoral Asset Management||2.27M||$24.04M||Sept. 30, 2014|
Who sold ImmunoGen?
|Fund Name||Date Sold||Number of Shares Sold||Share Valuation|
|Norges Bank Investment Management||Dec. 31, 2013||2.37M||$34.81M|